Anna M. Brannen
FDA investigator
Appears on 2 documents from 2009 to 2026, mostly at sites in India. Most often cites production record review (21 CFR 211.192).
- 2
- Documents on file
- 8.0
- Observations per 483
- 2009
- First seen
- 2026
- Most recent
What they cite most
From 16 observations- 21 CFR 211.192Production record review2
- 21 CFR 211.25Personnel qualifications2
- 21 CFR 211.100Written procedures; deviations1
- 21 CFR 211.113Control of microbiological contamination1
- 21 CFR 211.180General requirements1
- 21 CFR 211.194Laboratory records1
Activity by year
2009: 1, 2026: 1
Where
India 1 · Ohio 1
Often inspects with
Is Anna M. Brannen coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2026-04-17 | 483 Cliantha Research LimitedApr 17, 2026 · Ahmedabad, India | Ahmedabad, India | 6 | |
| 2009-12-23 | 483 Amylin Pharmaceuticals Inc.Dec 23, 2009 · West Chester, Ohio | West Chester, Ohio | 10 |
About this profile
What does Anna M. Brannen inspect?
Anna M. Brannen appears on 2 documents on file covering 2 sites, mostly in India.
What do they cite most often?
21 CFR 211.192 (production record review), followed by 21 CFR 211.25 and 21 CFR 211.100.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Anna M. Brannen is dated Apr 17, 2026.